AmoyDx participates in the ECP 2022
AmoyDx is happy to have attended and exhibited at the 34th European Congress of Pathology (ECP 2022) held from 3 to 7 September 2022 at the Congress Centre in the middle of the city of Basel, Switzerland.
Investigators Present Significant Research During WCLC 2022
Several key researches supported by Amoy Diagnostics were presented at WCLC 2022. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from mor
AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation
Vienna – Aug. 7th, 2022. – A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping).
Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership
The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Pharmaceuticals Campus, where participants had discussions on recent progresses in this field.
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,
AmoyDx is excited to join the IASLC 2022 World Conference on Lung Cancer (Booth# 307), held in person with virtual elements in Vienna, Austria from August 6 – 9, 2022.